15876-67-2
Chemical Structure
Ubretid
Synonym(s): Distigmine dibromide
- CAS No.: 15876-67-2
- Formula:C22H32Br2N4O4
- Molecular Weight:576.32
IUPAC Name: 3,3'-(((hexane-1,6-diylbis(methylazanediyl))bis(carbonyl))bis(oxy))bis(1-methylpyridin-1-ium) bromide
InChIKey: GJHSNEVFXQVOHR-UHFFFAOYSA-L
SMILES: O=C(N(C)CCCCCCN(C)C(OC1=C[N+](C)=CC=C1)=O)OC2=C[N+](C)=CC=C2.[Br-].[Br-]
Biological Activity: Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ubretid | 99.0% | Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ubretid (Standard) | ≥98% | Ubretid (Standard) is the analytical standard of Ubretid. This product is intended for research and analytical applications. Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
